Ocular Therapeutix, Inc.
DE ˙ DB ˙ US67576A1007
€ 7,15 ↑0.25 (3.62%)
2026-06-04
PREÇO DA AÇÃO
SecurityDE:0OT / Ocular Therapeutix, Inc.
InstitutionAlgert Global Llc
Latest Disclosed Ownership538,939 shares
Latest Disclosed Value $ 4,565
Algert Global Llc reports 323.00% increase in ownership of 0OT / Ocular Therapeutix, Inc.

On May 14, 2026 - Algert Global Llc filed a 13F-HR form disclosing ownership of 538,939 shares of Ocular Therapeutix, Inc. (DE:0OT) valued at $3,580,711 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 127,410 shares of Ocular Therapeutix, Inc.. This represents a change in shares of 323.00% during the quarter. The current value of the position is $3,853,414 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F OCULAR THERAPEUTIX COM 67576A100 538,939 411,529 323.00 5 300.00 0.0687
2026-02-17 2025-12-31 13F OCULAR THERAPEUTIX COM 67576A100 127,410 127,410 2 0.0241
2025-08-14 2025-06-30 13F OCULAR THERAPEUTIX COM 67576A100 0 -29,020 -100.00 0 0.0000
2025-05-13 2025-03-31 13F OCULAR THERAPEUTIX COM 67576A100 29,020 29,020 0 0.0053
2024-11-12 2024-09-30 13F OCULAR THERAPEUTIX COM 67576A100 0 -10,114 -100.00 0 0.0000
2024-08-15 2024-06-30 13F OCULAR THERAPEUTIX COM 67576A100 10,114 10,114 0 0.0023
2024-02-14 2023-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -25,480 -100.00 0 0.0000
2023-11-13 2023-09-30 13F OCULAR THERAPEUTIX COM 67576A100 25,480 -23,750 -48.24 0 0.0038
2023-08-14 2023-06-30 13F OCULAR THERAPEUTIX COM 67576A100 49,230 49,230 0 0.0111
2023-02-13 2022-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -73,590 -100.00 0 -100.00
2022-11-15 2022-09-30 13F OCULAR THERAPEUTIX COM 67576A100 73,590 5,310 7.78 305 11.31 0.0184
2022-08-15 2022-06-30 13F OCULAR THERAPEUTIX COM 67576A100 68,280 56,423 475.86 274 364.41 0.0206
2022-05-16 2022-03-31 13F OCULAR THERAPEUTIX COM 67576A100 11,857 11,857 59 0.0039
2022-02-14 2021-12-31 13F OCULAR THERAPEUTIX COM 67576A100 0 -10,100 -100.00 0 -100.00
2021-11-15 2021-09-30 13F OCULAR THERAPEUTIX COM 67576A100 10,100 10,100 101 0.0134
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.